VNRX Form 4: Director Kim Nguyen Awarded 17,424 RSUs (Aug 2025)
VolitionRx Limited (VNRX) director Kim Nguyen was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 in lieu of cash compensation under the companys 2015 Stock Incentive Plan.
Rhea-AI Filing Summary
VolitionRx Limited (VNRX) director Kim Nguyen was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 in lieu of cash compensation under the companys 2015 Stock Incentive Plan. The RSUs are earned in six approximately equal monthly installments beginning August 1, 2025, and once earned they remain subject to additional time-based vesting in two equal installments of 8,712 units on November 1, 2025 and February 1, 2026. Upon vesting and settlement, each RSU converts to one share of common stock. After the award, the reporting person beneficially owned 115,816 shares directly and 30,556 shares indirectly (by spouse).
Positive
- Director compensation awarded as RSUs instead of cash, conserving company cash resources as explicitly stated
- Clear vesting schedule with earning and vesting dates provided, offering transparency on when shares may be issued
Negative
- Potential dilution from conversion of 17,424 RSUs to common shares upon vesting, as explicitly stated
- No information on total outstanding shares is provided in the filing, so the dilution impact relative to share count cannot be assessed from this document alone
Insights
TL;DR: Director received time‑based RSUs replacing cash pay, with staggered earning and vesting through Feb 2026.
The award reflects a common practice of compensating directors with equity rather than cash. The RSU structure has two layers: monthly earning across six installments starting August 1, 2025, then additional time‑based vesting into two equal tranches on November 1, 2025 and February 1, 2026. This design ties ultimate share delivery to continued service through the vesting dates. The Form 4 discloses the directors direct and indirect holdings, enabling investors to track potential dilution timing and insider selling constraints once shares are issued.
TL;DR: The transaction is a routine director compensation award and is not a market‑moving event by itself.
Seventeen thousand four hundred twenty‑four RSUs at $0 price indicate compensation issuance rather than a market purchase. The filing shows 115,816 shares owned directly and 30,556 indirectly after the award, providing transparency on insider holdings. There are no derivative transactions reported. The timing and size of these RSUs are disclosed clearly, but the form contains no financial performance metrics or indications of material strategic changes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 17,424 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. On August 15, 2025, the reporting person was awarded 17,424 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs are earned in six approximately equal monthly installments commencing on August 1, 2025. Once earned, they will remain subject to additional time-based vesting in two equal installments of 8,712 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did VolitionRx (VNRX) report on Form 4 for Kim Nguyen?
Will the RSUs convert to common stock and when?
Was any cash paid for these RSUs?
Does the Form 4 show any derivative transactions by Kim Nguyen?
AI-generated analysis. How Rhea-AI works. Not financial advice.